Detailed Information
Cited 13 time in 
Cited 14 time in 
Cited 14 time in
Metadata Downloads
EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M MutationEGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation
- Other Titles
- EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation
- Authors
- Park, S[Park, Sehhoon]; Ku, BM[Ku, Bo Mi]; Jung, HA[Jung, Hyun Ae]; Sun, JM[Sun, Jong-Mu]; Ahn, JS[Ahn, Jin Seok]; Lee, SH[Lee, Se-Hoon]; Park, K[Park, Keunchil]; Ahn, MJ[Ahn, Myung-Ju]
- Issue Date
- Oct-2020
- Publisher
- KOREAN CANCER ASSOCIATION
- Keywords
- Non-small cell lung cancer; Lazertinib; Third-generation EGFR tyrosine kinase inhibitor; ErbB receptors
- Citation
- CANCER RESEARCH AND TREATMENT, v.52, no.4, pp.1288 - 1290
- Indexed
- SCIE
SCOPUS
KCI
- Journal Title
- CANCER RESEARCH AND TREATMENT
- Volume
- 52
- Number
- 4
- Start Page
- 1288
- End Page
- 1290
- ISSN
- 1598-2998
- Abstract
- The non-small cell lung cancer with activating epidermal growth factor receptor (EGFR) mutation eventually acquires resistant to either first or second-generation EGFR tyrosine kinase inhibitor (TKI). As the following option, targeting EGFR T790M with third-generation EGFR TKI is now established as a standard treatment option. In this study, we are reporting the first case of resistance mechanism to the novel third-generation EGFR TKI, lazertinib, which showed promising clinical efficacy in phase 1-2 study. The patients showed resistance to the treatment by acquiring the additional EGFR C797S mutation in cis which is also confirmed from the patient-derived cell lines.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.